A Phase 1 interventional study of ARM011 and Fludarabine in Acute Lymphoblastic Leukemia, sponsored by TriArm Therapeutics (Taiwan) Limited. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-23.
Sponsored by TriArm Therapeutics (Taiwan) Limited · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Taiwan — 4 open to participants now, 8 under way, 3 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Taiwan.
Among the 20 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Taiwan, this one is the 15th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 1, and was the 18th registered.
2,584 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →4 of the 20 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Taiwan are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Taiwan, Australia, France and 3 more countries
Ages 1–30
AstraZeneca · Sites in Taiwan, United States, Australia and 6 more countries
Ages 12+
Sumitomo Pharma America, Inc. · Sites in Taiwan, United States, Belgium and 9 more countries
Ages 12+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 7 · Phase 4 1
First in 2003; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 40 across 1,952 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 153 across the 16 interventional studies, 265 across the 4 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 20 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with TriArm Therapeutics (Taiwan) Limited as lead sponsor.
TriArm Therapeutics (Taiwan) Limited has 1 study filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
2 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Taiwan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04988555Sumitomo Pharma America, Inc.A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1 study to evaluate FIT-CD19-CAR-T (ARM011) safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
This is an open-label, single arm, Phase 1 study to evaluate the safety and tolerability of FIT-CD19-CAR-T (ARM011) administered intravenously (IV) following a standard lymphodepleting (LD) chemotherapy regimen of cyclophosphamide and fludarabine in subjects with relapsed/refractory acute lymphoblastic leukemia (ALL). This dose finding study will use a 3+3 design.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment with ARM011
Biological: ARM011 · Drug: Fludarabine · Drug: Cyclophosphamide
ARM011 is an autologous, CD19 targeted CAR T-cell product developed on fast-in-time (FIT) platform-a non-viral, 2-day rapid manufacturing process
Administered prior to infusion of ARM011
Administered prior to infusion of ARM011
Incidence of adverse events [Safety and Tolerability]
Safety and Tolerability: Proportion of subjects experiencing adverse events and dose-limiting toxicities
Time frame: Up to 24 months after ARM011 infusion
Evaluate cellular kinetics and persistence of ARM011
Cellular kinetics related peak (Cmax) in peripheral blood
Time frame: Up to 24 months after ARM011 infusion
Evaluate cellular kinetics and persistence of ARM011
Area under the concentration time curve (AUC) in peripheral blood
Time frame: Up to 24 months after ARM011 infusion
Evaluate preliminary anti-tumor activity of ARM011
Preliminary anti-tumor activity: Proportion of subjects with an objective response (including complete response or complete remission with incomplete count recovery)
Time frame: Up to 24 months after ARM011 infusion
Evaluate host immunogenicity to ARM011
Incidence of anti-CD19-directed CAR antibodies
Time frame: Up to 24 months after ARM011 infusion
Evaluate the feasibility of administration of ARM011
The proportion of subjects for whom a CAR T-cell product meeting specifications could be prepared, which will be computed with a corresponding 95% confidence interval (CI).
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Apr 2028, 32 months after the start.
Of 50 industry-sponsored phase 1 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 65. This study's planned 32 months is below that.
Counting every sponsor, half of 209 studies reached it within 57 months; a quarter within 35 and three quarters within 92.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma →